LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced that an abstract for CA-4948, a small molecule IRAK4
inhibitor, has been accepted for poster presentation at the
American Association for Cancer Research (AACR) Annual Meeting,
which will be held virtually from April
10-15, 2021.
Details of the presentation are as follows:
Poster Presentation
- Title: Identification of NF-kappaB phospho-p50 as a
Potential Predictive Biomarker for IRAK4 inhibitor CA-4948 in
Patients with Non-Hodgkin's Lymphoma
- Session Name: Biomarkers Predictive of Therapeutic
Benefit
- Session Date: Saturday, April 10,
2021
Additional meeting information can be found on the AACR website
https://www.aacr.org/meeting/aacr-annual-meeting-2021/. The
presentation will also be available under "Events and
Presentations" in the Investors section of the Company's website at
www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently
undergoing testing in a Phase 1 trial in patients with
non-Hodgkin's lymphoma both as a monotherapy and in combination
with BTK inhibitor, ibrutinib. Curis is also evaluating CA-4948 in
a Phase 1 trial in patients with acute myeloid leukemia and
myelodysplastic syndromes. In addition, Curis is engaged in a
collaboration with ImmuNext for development of CI-8993, a
monoclonal anti-VISTA antibody, which is currently undergoing
testing in a Phase 1a/1b trial in
patients with solid tumors. Curis is also party to a collaboration
with Genentech, a member of the Roche Group, under which Genentech
and Roche are commercializing Erivedge® for the treatment of
advanced basal cell carcinoma. For more information, visit Curis'
website at www.curis.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/curis-announces-abstract-for-ca-4948-accepted-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-301244538.html
SOURCE Curis, Inc.